Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK 9.56
-0.16 (-1.65%)
Aug 13, 2026, 5:23 PM CET
Xbrane Biopharma AB Market Cap
Xbrane Biopharma AB has a market cap or net worth of 196.99 million as of August 13, 2026. Its market cap has decreased by -55.85% in one year.
Market Cap
196.99M
Enterprise Value
211.20M
Revenue
83.30M
Ranking
n/a
PE Ratio
n/a
Stock Price
9.56
ChartMarket Cap Chart
Since February 3, 2016, Xbrane Biopharma AB's market cap has increased from 131.05M to 196.99M, an increase of 50.31%. That is a compound annual growth rate of 3.95%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 13, 2026 | 196.99M | -6.27% |
| Dec 30, 2025 | 210.17M | -14.54% |
| Dec 30, 2024 | 245.94M | -17.28% |
| Dec 29, 2023 | 297.31M | -86.83% |
| Dec 30, 2022 | 2.26B | -13.94% |
| Dec 30, 2021 | 2.62B | 58.03% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| IRLAB Therapeutics AB | 234.07M |
| Elicera Therapeutics AB | 197.87M |
| Alzinova AB | 186.83M |
| Initiator Pharma | 173.19M |
| Abera Bioscience AB | 166.45M |
| Diamyd Medical AB | 160.25M |
| Xintela AB | 155.89M |
| Biovica International AB | 152.96M |